Risk factors for grade 3/4 transaminase elevation in patients with chronic lymphocytic leukemia treated with idelalisib.

ABSTRACT:

SUBMITTER: Brown JR 

PROVIDER: S-EPMC7829041 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature